8-K current report · filed Nov 4, 2026

Sight Sciences, Inc. (SGHT) 8-K Current Report: November 4, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2SGHT overview

Short answer

Sight Sciences, Inc. (SGHT) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 results announced for quarter ended September 30, 2026.

Sight Sciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results announced for quarter ended September 30, 2026
  • Full-year 2026 revenue guidance raised, signaling improved expected sales performance
  • Detailed financial results and revised guidance in Exhibit 99.1 press release

Item 7.01 · Regulation FD Disclosure

  • Investor presentation posted November 4, 2026, intended for investor and analyst communications
  • Exhibit 99.2 contains the presentation, potentially including updated strategy, operating metrics, or financial guidance

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $24.9M, up 25% year over year, signaling accelerating commercial traction
  • IDE revenue $3.9M versus $0.2M, with 222 active customers and 4,581 treatment units sold
  • IG revenue $21.0M, up 7%, supported by 1,253 active customers versus 1,197
  • Net loss improved to $6.8M from $8.2M, while cash usage fell 74% to $2.4M
  • Full-year revenue guidance raised to $92M-$93M, including approximately $12M IDE revenue versus prior guidance of $9M-$11M

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 revenue $24.9M, up 25% YoY, marking a third consecutive quarter of double-digit growth
  • FY2026 revenue guidance $92M-$93M, up 19%-20% YoY, signaling accelerating commercial momentum
  • YTD adjusted operating expenses 99% of revenue versus 121% prior year, while cash usage improved 74%
  • Interventional dry eye revenue $7.9M versus $0.9M prior year, making TearCare the primary growth engine
  • OMNI Ultra launch, Aetna coverage, and expanded commercial targeting represent key catalysts, with reimbursement and execution as principal risks

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Sight Sciences, Inc. 8-K filings

Get the next SGHT 8-K as it lands

Follow SGHT for push alerts, or ask the research agent what this filing means.